FDA to Regulate Fecal Transplants

From now on, US physicians and researchers will have to get approval from the FDA before they can perform a stool transplant.

By | May 21, 2013

Scanning electron micrograph of Clostridium difficileWIKIMEDIA, CDCThe US Food and Drug Administration has decided that fecal transplants meet the definition of a biologic therapy, meaning that researchers and physicians who want to perform the procedure will now have to submit an investigational new drug (IND) application, MedPage Today reported last week (May 15).

Researchers performing the procedure—which has emerged as an effective way to treat resistant Clostridium difficile infection—were informed of the requirement in February. “The FDA has been clear for some time now that for fecal transplantation . . . it is necessary to have an IND for some type of regulation and oversight,” University of Chicago gastroenterologist David Rubin, who is involved in a trial of fecal transplant for ulcerative colitis, told MedPage Today.

Some researchers and clinicians are concerned that the new requirements, which involve lots of paperwork and a 30-day wait, will restrict access to a promising therapy. Michael Edmond, a researcher and physician at Virginia Commonwealth University, wrote on the Controversies in Hospital Infection Prevention blog that the ruling “imposes a huge bureaucratic hurdle to getting a much-needed therapy for patients with recurrent or intractable C. difficile infection.”

Infectious disease specialist Judy Stone agreed. Writing on her Molecules to Medicine blog, she argued that “the FDA [should] exclude non-academic/non-research centers from the IND requirement, or centers that want to perform less than X number of procedures per month. . . . Otherwise, physicians will increasingly give patients directions for home, do-it-yourself (DIY) treatments.”

But Herbert DuPont, a researcher at the University of Texas Medical School who is planning a fecal transplantation trial, told MedPage Today that while he was disappointed about the added expense and time, he understood the FDA’s desire to set safety standards for the procedure. “Am I disappointed? Yes,” he said. “Do I have problems with the outcome? Absolutely not.”

Add a Comment

Avatar of: You

You

Processing...
Processing...

Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  2. Athletes’ Microbiomes Differ from Nonathletes
  3. Mutation Linked to Longer Life Span in Men
  4. Gut Feeling
    Daily News Gut Feeling

    Sensory cells of the mouse intestine let the brain know if certain compounds are present by speaking directly to gut neurons via serotonin.

AAAS